- Conditions
- Prostate Cancer
- Interventions
- tarenflurbil, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Myrexis Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 58
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Fresno, California + 49 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 84,011
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C
- Interventions
- Integrated care model, Usual Care Model
- Behavioral
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 3
- States / cities
- Palo Alto, California • San Diego, California • The Bronx, New York
- Conditions
- Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Interventions
- pomalidomide, bortezomib, dexamethasone, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Boston, Massachusetts • Detroit, Michigan + 1 more
- Conditions
- Empty Nose Syndrome, Atrophic Rhinitis
- Interventions
- Botulinum Toxin Type A
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine)
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Temecula, California • Minneapolis, Minnesota • Portland, Oregon
- Conditions
- Endometrial Adenocarcinoma
- Interventions
- ACR-368, Gemcitabine, OncoSignature
- Drug · Diagnostic Test
- Lead sponsor
- Acrivon Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more
- Conditions
- Hematological Malignancy, Neutropenia
- Interventions
- Eravacycline
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- Osteoarthritis, Arthritis
- Interventions
- Negative Work, Stretching
- Other
- Lead sponsor
- Washington D.C. Veterans Affairs Medical Center
- Federal
- Eligibility
- 50 Years to 70 Years · Male only
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
- Interventions
- decitabine, pharmacological study, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Cancer, Tumor, Solid, Refractory Cancer
- Interventions
- TBX-3400
- Biological
- Lead sponsor
- Taiga Biotechnologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Thyroid, PD-1, Cancer
- Interventions
- blood draw and questionnaire completion, questionnaire completion, blood collection
- Other
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Alcohol Use Disorder
- Interventions
- Standard treatment (ST) PLUS web-based CBT4CBT, Standard Treatment (ST)
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Bridgeport, Connecticut • New Haven, Connecticut
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- PET/MRI, Percutaneous ablation, Stereotactic body radiotherapy
- Device · Radiation
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Alzheimer's Disease
- Interventions
- Bexarotene, Placebo
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Brain Metastases, HR+ Metastatic Breast Cancer
- Interventions
- Stereotactic Radiosurgery (SRS), Abemaciclib, Endocrine therapy
- Radiation · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Columbus, Ohio
- Conditions
- Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
- Interventions
- Laboratory Biomarker Analysis
- Other
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 275 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1992
- U.S. locations
- 187
- States / cities
- Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
- Conditions
- Neck Pain
- Interventions
- manual therapy, exercise
- Other
- Lead sponsor
- Franklin Pierce University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Concord, New Hampshire
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Radiopharmaceutical 18F-FSPG
- Diagnostic Test
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Irritable Bowel Syndrome, Bacterial Overgrowth Syndrome, SIBO
- Interventions
- Atrantil (Medical Food)
- Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Fludarabine, CAR-T Cells
- Drug · Biological
- Lead sponsor
- Benjamin Tomlinson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2036
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • Cleveland, Ohio
- Conditions
- Cholangiocarcinoma, Liver Neoplasms
- Interventions
- Floxuridine, Dexamethasone, Gemcitabine, Oxaliplatin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Interventions
- Tegaserod
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 30 participants
- Timeline
- 2004 – 2005
- U.S. locations
- 7
- States / cities
- Boynton Beach, Florida • Miami, Florida • Pembroke Pines, Florida + 4 more
- Conditions
- Diabetes Mellitus
- Interventions
- Exenatide, Exenatide matching placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 68
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 56 more
- Conditions
- Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
- Interventions
- Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
- Drug · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 441
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more